Ovid Therapeutics Operating Income Over Time
| OVID Stock | USD 1.05 0.01 0.94% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ovid Therapeutics Performance and Ovid Therapeutics Correlation. Ovid |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.009 | Quarterly Revenue Growth 0.587 | Return On Assets (0.36) | Return On Equity (0.37) |
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Ovid Therapeutics and related stocks such as CytomX Therapeutics, Spero Therapeutics, and Neoleukin Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTMX | (15 M) | (15 M) | (15 M) | (15 M) | (29.8 M) | (33.2 M) | (59.6 M) | (46.3 M) | (77.9 M) | (110.9 M) | (48.6 M) | (83.8 M) | (101.3 M) | (6.5 M) | (6.8 M) |
| SPRO | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (33.2 M) | (41.7 M) | (42.8 M) | (63.2 M) | (79.1 M) | (88 M) | (42.2 M) | 21.5 M | 22.6 M |
| TIL | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (33.6 M) | (155.6 M) | (226.5 M) | (159.2 M) | (167.1 M) |
| NXTC | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (23.2 M) | (37.5 M) | (41.2 M) | (70.8 M) | (75.9 M) | (67.6 M) | (71 M) |
| ASMB | (7.2 M) | (34 M) | (24.9 M) | (19.6 M) | (24 M) | (29.7 M) | (45.3 M) | (52.2 M) | (92.7 M) | (102.7 M) | (64.8 M) | (132.7 M) | (94.1 M) | (64.6 M) | (67.9 M) |
| ACHL | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (33.7 M) | (64.2 M) | (78.4 M) | (75.3 M) | (79 M) |
| NUVB | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (32.1 M) | (43.6 M) | (93.3 M) | (119.7 M) | (99.8 M) | (104.8 M) |
| CNTB | (110.2 M) | (110.2 M) | (110.2 M) | (110.2 M) | (110.2 M) | (110.2 M) | (110.2 M) | (110.2 M) | (110.2 M) | (110.2 M) | (30.3 M) | (99.2 M) | (117.7 M) | (62.1 M) | (65.2 M) |
Ovid Therapeutics and related stocks such as CytomX Therapeutics, Spero Therapeutics, and Neoleukin Therapeutics Operating Income description
Operating Income is the amount of profit realized from Ovid Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Ovid Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Ovid Therapeutics | OVID |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.05
Check out Ovid Therapeutics Performance and Ovid Therapeutics Correlation. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Ovid Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.